Optimizing Treatment Sequencing for HR+/HER2- Metastatic Breast Cancer Based on Emerging Evidence and Evolving Algorithms
Optimizing Treatment Sequencing for HR+/HER2- Metastatic Breast Cancer Based on Emerging Evidence and Evolving Algorithms is organized by Physicians' Education Resource, LLC (PER).
Release Date: March 31, 2023
Expiration Date: March 31, 2024
Description:
This online, on-demand virtual symposium brings together renowned experts in the management of hormone receptor-positive, HER2-negative metastatic breast cancer (HR+/HER2- MBC). It features a discussion about how treatment of these tumors can be individualized across the continuum of metastatic disease and includes real-world case examples to highlight the clinical implications of recent evidence and ongoing trials of currently approved and emerging therapies. Topics include recent data from trials of CDK4/6 inhibitors, PI3K/AKT/mTOR inhibitors, antibody-drug conjugates, PARP inhibitors, and novel SERDs, and the application of this evidence into clinical practice; how treatment paradigms and best practices are evolving; and the management of potential adverse events associated with these therapies. Experts will discuss how they leverage key data sets to support decision-making regarding initiating, sequencing, monitoring, and switching therapies.
This educational activity is an archive of the live symposium that was held on March 4, 2023.
Learning Objectives:
Upon completion of this activity, participants will be able to:
• Evaluate clinical trial evidence supporting current treatment algorithms and available agents for HR+/HER2- metastatic breast cancer (MBC), including CDK4/6 inhibitors, PI3K/mTOR inhibitors, PARP inhibitors, and antibody-drug conjugates (ADCs)
• Integrate strategies for individualizing treatment selection and sequencing for patients with HR+/HER2- MBC, incorporating biomarkers, tumor characteristics, patient attributes, comorbidities, and patient desires
• Develop tactics for proactively managing adverse events associated with treatments for patients with HR+/HER2- MBC, to enhance patient adherence to oral anticancer therapies
• Review investigational therapies for HR+/HER2- MBC, including oral selective estrogen receptor degraders, ADCs, and other targeted agents, and how emerging data may impact current treatment paradigms and address unmet clinical needs in the near future